Free light chains, kappa (κ) lambda (λ), are produced by plasma cells and known to be an important marker in patients with Multiple Myeloma and AL Amyloidosis. The precursor condition to Multiple ...
Serum free light chain (sFLC) tests have advanced the prediction, diagnosis, and monitoring of plasma cell disorders. This webinar features two leading experts who will compare the performance of sFLC ...
Cox proportional hazards models, adjusting for death as a competing risk, were used to evaluate the 20–20–20 system. The Sebia assay appears to perform as well in the 20-20-20 system as does the ...
The clinical impact of these findings are substantial. It allows better identification of individuals with true monoclonal gammopathies and on the other side can avoid unnecessary referrals and ...
MM often goes undetected until its later stages because it presents with non-specific symptoms, including fatigue, weight loss, bone pain, and recurrent infections. 2,3 However, better awareness, ...
Free light chain (FLC) kappa and lambda Assays for Atellica ® NEPH 630*, BN TM II, and BN ProSpec ® Systems are developed for more reliable managment of patients with monoclonal gammopathies. Improved ...
Current standard modalities for detecting and quantifying monoclonal immunoglobin in patients with cold agglutinin disease lack adequate sensitivity. Heavy chain/light chain assay may be more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results